Evicenter
Kesimpta (ofatumumab) in Relapsing multiple sclerosis
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kesimpta (opens in a new tab)
Questions
73
Last updated

All questions

Clinical trials: Kesimpta (ofatumumab) in relapsing multiple sclerosis

6 questions · 3 sources

Clinical trials

How were the Kesimpta ASCLEPIOS I and II trials designed?

Kesimpta vs Aubagio (teriflunomide): how much lower was the relapse rate?

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2.

Does Kesimpta slow disability progression compared with Aubagio (teriflunomide)?

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2. The kesimptahcp.com clinical trial results page gives 0.65 points for a baseline EDSS of 5.5 or greater in a footnote to a post hoc subgroup analysis; the Prescribing Information, the FAQ page, and the Authorization and Appeals Kit give 0.5 points.

How much does Kesimpta reduce MS lesions on MRI compared with Aubagio?

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2.

Long-term results

How many Kesimpta patients had no evidence of disease activity in year 7 (ALITHIOS)?

What were Kesimpta disability progression rates at 7 years (ALITHIOS extension)?